Clinical Trials on PK, PD, and Safety in Australia
Total 29 results
-
MingSight Pharmaceuticals Pty LimitedCompletedSafety and PK in Healthy VolunteersAustralia
-
Island PharmaceuticalsBeyond Drug DevelopmentCompletedSafety and TolerabilityAustralia
-
Annexon, Inc.Nucleus Network LtdCompletedSafety and Tolerability in Healthy VolunteersAustralia
-
Annexon, Inc.TerminatedSafety and Tolerability in Healthy VolunteersAustralia
-
Biotronik SE & Co. KGCompletedSafety of MR (Magnetic Resonance) Conditional CRT-pacemakers and ICDsFrance, Germany, Hungary, Canada, Australia, Austria, Czech Republic, Switzerland
-
University Hospital, Basel, SwitzerlandCompletedPostoperative Complications | Intraoperative Complications | Patient Safety | Risk ManagementNew Zealand, Switzerland, United States, Netherlands, Spain, Austria, Turkey, United Kingdom, Australia, Greece, Ireland, Italy
-
BlueSky Immunotherapies GmbHEnrolling by invitation
-
Ascendis Pharma Oncology Division A/SRecruitingAdvanced Solid Tumor | Metastatic Solid Tumor | Platinum-resistant Ovarian Cancer | Locally Advanced Solid Tumor | Post Anti-PD-1 Melanoma | 2L+ Cervical Cancer | Neoadjuvant Melanoma | Neoadjuvant Non-Small Cell Lung Cancer | Post Anti-PD-(L)1 Non-Small Cell Lung Cancer | Post Anti-PD-(L)1 Small Cell...United States, Australia, Korea, Republic of
-
Medical University of ViennaUnknownGlaucoma | Safety Issues | Efficacy, Self | Post-Op Complication | Glaucoma SurgeryAustria
-
Medical University InnsbruckCompletedEmergencies | Pain, Acute | Trauma, Multiple | Safety | Analgesics | Accident | Field Physician Care | HypnoticsAustria
-
BeiGeneRecruitingLocally Advanced or Metastatic Solid Tumors for Phase 1,Dose Escalation and Phase 2 Safety Lead-in, HNSCC, NSCLC and RCC Participants for Phase 2Australia, United States, Spain, France, Italy, Korea, Republic of, Poland
-
Novartis PharmaceuticalsActive, not recruitingLocally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutationSpain, Italy, Austria, Netherlands, United Kingdom, Germany, Thailand, France, Belgium, China, Argentina, Greece, Turkey, Malaysia, Portugal, Hungary, Brazil, United States, India
-
Novartis PharmaceuticalsUniversity of PennsylvaniaRecruitingLong Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access ProgramUnited States, Japan, Australia, Germany, Spain, Belgium, Taiwan, Italy, Canada, Israel, Singapore, United Kingdom, Denmark, Finland, Norway, Austria, Netherlands, France
-
AbbVieActive, not recruitingParkinson's Disease (PD)United States, Australia, Belgium, Canada, Denmark, Germany, Italy, Japan, Netherlands, Russian Federation, Spain, Sweden, United Kingdom
-
AbbVieActive, not recruitingParkinson's Disease (PD)United States, Australia
-
AmgenCompletedEvaluate the Safety and Efficacy of Denosumab in Pediatric Subjects With | Glucocorticoid-induced OsteoporosisUnited States, Bulgaria, Turkey, Italy, Australia, Belgium, Canada, Colombia, India, Mexico, Peru, Russian Federation, Ukraine
-
AbbVieCompletedParkinson's Disease (PD)United States, Australia, Belgium, Canada, Denmark, Germany, Italy, Japan, Netherlands, Russian Federation, Spain, Sweden, United Kingdom
-
AbbVieCompletedParkinson's Disease (PD)United States, Australia
-
Gilead SciencesMerck Sharp & Dohme LLCRecruitingTriple Negative Breast Cancer | PD-L1 PositiveUnited States, Taiwan, Belgium, Australia, Austria, Israel, Spain, Italy, Korea, Republic of, Japan, France, Netherlands, Canada, Turkey, Germany, Malaysia, Singapore, United Kingdom, Hong Kong, Hungary, Mexico, Switzerland, Puerto... and more
-
Gilead SciencesRecruitingTriple Negative Breast Cancer | PD-L1 NegativeUnited States, Hong Kong, Belgium, Australia, Austria, Israel, Spain, Korea, Republic of, Taiwan, China, Japan, Netherlands, Brazil, Canada, Turkey, France, Germany, Malaysia, United Kingdom, Singapore, Hungary, Mexico, Italy, Switzer... and more
-
Novartis PharmaceuticalsCompletedLong-term Safety of TIPItaly, Spain, Germany, United States, Australia, Canada, Hungary, Mexico, Argentina
-
AbbVieCompletedParkinson's Disease (PD)Austria, Canada, Croatia, Czechia, Greece, Hungary, Ireland, Israel, Romania, Spain, Sweden
-
Boehringer IngelheimCompletedEarly Parkinson Disease (Early PD)United States, Argentina, Austria, Czech Republic, Finland, Germany, Hungary, India, Japan, Malaysia, Russian Federation, Slovakia, Taiwan, Ukraine
-
Adamas Pharmaceuticals, Inc.CompletedParkinson's Disease (PD) | Dyskinesia | Levodopa-Induced Dyskinesia (LID)France, Spain, United States, Germany, Austria
-
Adamas Pharmaceuticals, Inc.CompletedParkinson's Disease (PD) | Dyskinesia | Levodopa Induced Dyskinesia (LID)France, Spain, United States, Canada, Germany, Austria
-
Theravance BiopharmaTerminatedParkinson's Disease (PD) | MSA | Symptomatic Neurogenic Orthostatic Hypotension | Pure Autonomic Failure (PAF)United States, Spain, United Kingdom, Canada, France, Estonia, Australia, Israel, Denmark, Italy, Poland, New Zealand, Germany, Ukraine, Austria, Bulgaria, Portugal, Hungary, Russian Federation
-
Incyte CorporationActive, not recruitingCervical Cancer | Nasopharyngeal Carcinoma | Mesothelioma | Advanced Solid Tumor | Small-cell Lung Cancer | Esophageal Squamous Cell Carcinoma | Urothelial Carcinoma | Merkel Cell Carcinoma | HepatoCellular Carcinoma | Cutaneous Squamous Cell Carcinoma | MSI-H/dMMR Tumors | PD-L1 Amplified Tumor (9p24.1)France, United States, Japan, Belgium, Australia
-
AstraZenecaCompletedRecurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHNUnited States, France, Italy, Spain, Belgium, Czechia, Romania, Taiwan, Korea, Republic of, Brazil, Hungary, Japan, Russian Federation, Australia, Germany, Israel, Serbia, Bulgaria, Ukraine, Argentina, Poland, Chile, Croatia, Georgia
-
Novartis PharmaceuticalsCompletedMetastatic Colorectal Cancer | Gastric Cancer | Advanced Solid Tumors | Metastatic Breast Cancer | Gastroesophageal Junction Cancer | Recurrent Glioblastoma Multiforme | Advanced Pancreatic Adenocarcinoma | Safety | Triple Negative Metastatic Breast Cancer | Dose Escalation | Preliminary Efficacy | Hormone Receptor...Canada, United Kingdom, Spain, Germany, Italy, Belgium, Australia, United States